{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:09:22Z","timestamp":1793329762750,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,12,15]]},"abstract":"<jats:p> PURPOSE: Although all studies confirm that BRCA1 tumors are highly proliferative and poorly differentiated, their outcomes remain controversial. We propose to examine, through a cohort study, the pathologic characteristics, overall survival, local recurrence, and metastasis-free intervals of 40 patients with BRCA1 breast cancer. <\/jats:p><jats:p> PATIENTS AND METHODS: A cohort of 183 patients with invasive breast cancer, treated at the Institut Curie and presenting with a familial history of breast and\/or ovarian cancer, were tested for BRCA1 germ-line mutation. Tumor characteristics and clinical events were extracted from our prospectively registered database. <\/jats:p><jats:p> RESULTS: Forty BRCA1 mutations were found among the 183 patients (22%). Median follow-up was 58 months. BRCA1 tumors were larger in size (P = .03), had a higher rate of grade 3 histoprognostic factors (P = .002), and had a higher frequency of negative estrogen (P = .003) and progesterone receptors (P = .002) compared with non-BRCA1 tumors. Overall survival was poorer for carriers than for noncarriers (5-year rate, 80% v 91%, P = .002). Because a long time interval between cancer diagnosis and genetic counseling artificially increases survival time due to unrecorded deaths, the analysis was limited to the 110 patients whose diagnosis-to-counseling interval was less than 36 months (19 BRCA1 patients and 91 non-BRCA1 patients). The differences between the BRCA1 and non-BRCA1 groups regarding overall survival and metastasis-free interval were dramatically increased (49% v 85% and 18% v 84%, respectively). Multivariate analysis showed that BRCA1 mutation was an independent prognostic factor. <\/jats:p><jats:p> CONCLUSION: Our results strongly support that among patients with familial breast cancer, those who have a BRCA1 mutation have a worse outcome than those who do not. <\/jats:p>","DOI":"10.1200\/jco.2000.18.24.4053","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:42:41Z","timestamp":1487918561000},"page":"4053-4059","source":"Crossref","is-referenced-by-count":148,"title":["Familial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations"],"prefix":"10.1200","volume":"18","author":[{"given":"Dominique","family":"Stoppa-Lyonnet","sequence":"first","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ansquer","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Dreyfus","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Gautier","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gauthier-Villars","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwige","family":"Bourstyn","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna B.","family":"Clough","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Magdel\u00e9nat","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Pouillart","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fourquet","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Asselain","sequence":"additional","affiliation":[{"name":"From the Departments of Oncology Genetics, Biostatistics, Radiotherapy, Surgery, Pharmacology, Medical Oncology, and Pathology, Institut Curie, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0561","doi-asserted-by":"publisher","DOI":"10.1126\/science.7545954"},{"key":"R2-0561","doi-asserted-by":"publisher","DOI":"10.1038\/378789a0"},{"key":"R3-0561","doi-asserted-by":"publisher","DOI":"10.1038\/ng0396-333"},{"key":"R4-0561","unstructured":"Szabo  CI,   King  MC:   Population genetics of  and. BRCA2.   Am J Hum Genet 60:  1013,1997-1020,   BRCA1"},{"key":"R5-0561","doi-asserted-by":"crossref","unstructured":"Jacquemier  J,   Eisinger  F,   Birnbaum  D,  et al:  Histoprognostic grade in -associated breast cancer.   Lancet 345:  1503,1995  (letter)BRCA1","DOI":"10.1016\/S0140-6736(95)91060-3"},{"key":"R6-0561","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W"},{"key":"R7-0561","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10109-4"},{"key":"R8-0561","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W"},{"key":"R9-0561","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.15.1138"},{"key":"R10-0561","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S"},{"key":"R11-0561","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800811038"},{"key":"R12-0561","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(98)00023-1"},{"key":"R13-0561","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.3.259"},{"key":"R14-0561","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.397"},{"key":"R15-0561","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1642"},{"key":"R16-0561","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07065-7"},{"key":"R17-0561","unstructured":"Foulkes  WD,   Wong  N,   Brunet  JS,  et al:  Germline  mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.   Clin Cancer Res 3:  2465,1997-2469,   BRCA1"},{"key":"R18-0561","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79248-5"},{"key":"R19-0561","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2112"},{"key":"R20-0561","unstructured":"Stoppa-Lyonnet  D,   Laurent-Puig  P,   Essioux  L,  et al:   sequence variations in 160 individuals referred to a breast\/ovarian cancer clinic.   Am J Hum Genet 60:  1021,1997-1030,   BRCA1"},{"key":"R21-0561","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(97)90574-9"},{"key":"R22-0561","unstructured":"Mantel  N:   Evaluation of survival data and two new rank order statistics arising in its consideration.   Cancer Chemother Rep 50:  163,1966-170,"},{"key":"R23-0561","doi-asserted-by":"crossref","unstructured":"Cox  DR:   Regression models and life tables.   J R Stat Soc 34:  187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R25-0561","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3653"},{"key":"R26-0561","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3017"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.24.4053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:35:04Z","timestamp":1653514504000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.24.4053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12,15]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2000,12,15]]}},"alternative-id":["10.1200\/JCO.2000.18.24.4053"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.24.4053","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12,15]]}}}